Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | CTSA | P10619 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8070648 | 0.87 | PDE4B (0.42) | PDE4BPDE4DHCRTR1HCRTR2ADRA1D | |
| SCHEMBL3791481 | 0.85 | PDE4B (0.58) | PDE4BPDE4D | |
| SCHEMBL15906127 | 0.78 | PDE4B (0.47) | NLRP3PDE4BHCRTR1HCRTR2 | |
| SCHEMBL15906182 | 0.77 | BDKRB1 (0.43) | NLRP3ADRA1DADRA1AMTNR1AMTNR1B | |
| SCHEMBL15906129 | 0.76 | PDE4B (0.47) | NLRP3PDE4BHCRTR1HCRTR2ADRA1D | |
| SCHEMBL15906184 | 0.76 | BDKRB1 (0.44) | NLRP3ADRA1DADRA1AMTNR1AMTNR1B | |
| SCHEMBL15906181 | 0.74 | PDE4B (0.49) | PDE4BPDE4DCTSA | |
| SCHEMBL15906102 | 0.74 | PDE4B (0.49) | PDE4BPDE4DCTSA | |
| SCHEMBL15906187 | 0.74 | PDE4B (0.49) | PDE4BPDE4DCTSA | |
| SCHEMBL8066164 | 0.71 | PDE4B (0.44) | PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2014-10-09 | — | — | US | disclosed |
| US-8791267-B2 | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders | DECODE GENETICS EHF (IS) | 2014-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301999-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | NLRP3 728/4885PDE4B 2/4885PDE4D 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.